CA · State regulatory reference
California.
Restrictive
Aggressive enforcement against unlicensed peptide prescribing. The Medical Board of California has issued multiple cease-and-desist letters since 2023 to wellness clinics dispensing peptides without a documented in-person evaluation. AB-2098 (effective 2023) tightened the telehealth standard-of-care framework that governs initial encounters.
Last reviewed · 2026-05-25 · verified entry
Agencies
TPC notes
Telehealth
Allowed but tightly scoped. Initial visits typically require synchronous video; some peptide-related controlled-substance categories require an in-person exam.
Compounding
503A pharmacies operate but face active board oversight. The California State Board of Pharmacy has flagged out-of-state shipments of compounded GLP-1s in recent enforcement letters.
Sources